Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment

Table 6 Cox survival analysis of predictors of local progression-free survival in 316 patients with 404 hepatocelluar carcinomas after radiofrequency ablation

Characteristic	Univariate			Multivariate
	HR	95%CI	P value	HR	95%CI	P value
Sex	1.073	0.691-1.667	0.753
Age	0.796	0.559-1.133	0.205
Pathological grade	2.258	1.506-3.385	< 0.001
Etiology of cirrhosis	0.851	0.725-0.999	0.048
Portal vein hypertension	1.826	1.288-2.589	0.001
Liver function enzyme	1.082	0.740-1.583	0.684
(AST/ALT)
Child-Pugh classification	2.930	2.169-3.958	< 0.001	2.416	1.713-3.409	< 0.001
Serum AFP	1.425	1.010-2.011	0.044
CEUS pre-RFA	0.421	0.297-0.598	< 0.001
Number of tumors	1.765	1.212-2.570	0.003	1.588	1.031-2.447	0.036
Tumor size	1.587	1.104-2.283	0.013
Risky location	1.442	1.013-2.054	0.042
Type of RFA electrodes	0.449	0.264-0.764	0.003
Primary technical success	1.772	0.877-3.583	0.111
Number of RFA sessions	1.574	1.201-2.061	0.001	1.550	1.183-2.033	0.002

HCC: Hepatocelluar carcinoma; HR: Hazard ratio; AFP: Alpha–fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CEUS: Contrast enhanced ultrasound; RFA: Radiofrequency ablation.